145918-75-8 Usage
Description
TROXACITABINE is a nucleoside analogue, which is a type of compound that resembles the structure of natural nucleosides, the building blocks of DNA and RNA. It possesses potential anticancer properties and has been investigated for its effectiveness in treating various types of cancer.
Uses
Used in Anticancer Applications:
TROXACITABINE is used as an anticancer agent for patients with refractory lymphoproliferative diseases. It works by incorporating itself into the DNA of cancer cells, thereby inhibiting their replication and ultimately leading to cell death. This makes it a valuable tool in the fight against cancer, particularly for patients who do not respond well to traditional chemotherapy treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 145918-75-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,5,9,1 and 8 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 145918-75:
(8*1)+(7*4)+(6*5)+(5*9)+(4*1)+(3*8)+(2*7)+(1*5)=158
158 % 10 = 8
So 145918-75-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6?,7-/m0/s1
145918-75-8Relevant articles and documents
MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER
-
Page/Page column 14, (2021/10/22)
Use of lenvatinib, or a pharmaceutically acceptable salt thereof in combination with a compound of the formula MIV-818: (MIV-818) or pharmaceutically acceptable salt thereof, in the treatment of liver cancer or liver metastases. The respective dosage regimes of the compounds can be delivered concurrently or alternately.
Troxacitabine synthesis and crystalline forms
-
Paragraph 0058; 0059; 0060; 0061, (2016/10/27)
The present invention provides a troxacitabine synthesis method and troxacitabine crystallization methods. Further, the present invention also provides troxacitabine crystalline forms and application.
L-β-(2S,4S)- and L-α-(2S,4R)-dioxolanyl nucleosides as potential anti- HIV agents: Asymmetric synthesis and structure-activity relationships
Kim,Schinazi,Shanmuganathan,Jeong,Beach,Nampalli,Cannon,Chu
, p. 519 - 528 (2007/10/02)
In order to study the structure-activity relationships of L-(2S,4S)- and L-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents, various enantiomerically pure L-(2S,4S)- and (2S,4R)-dioxolanylpyrimidine and - purine nucleosides have been synthesize